Instrument Inactif

Autres langues Acasti Pharma Inc Toronto S.E.

Actions

APO

CA00430K4028

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights	12/02
Acasti: Fiscal Q3 Earnings Snapshot	12/02
Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	12/02
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial	01/02
Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial	01/02
Acasti Pharma Inc. Approves Appointment of Robert J. Delaversano, as Principal Financial Officer and Principal Accounting Officer	08/01
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024	13/12
Brain Hemorrhage Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	14/11
Acasti: Fiscal Q2 Earnings Snapshot	13/11
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights	13/11
Acasti Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	13/11
Aker BioMarine Gains Krill Assets from Acasti Pharma in $3.1 Million Settlement Deal	24/10/23
Aker BioMarine acquires patents, equipment, and scientific data from Acasti Pharma Inc	24/10/23
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial	23/10/23
Acasti Pharma Inc. Announces Board Changes	11/10/23
Acasti Pharma to Host KOL Event on GTX-104, A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage	05/10/23
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)	04/10/23
Acasti Pharma Insider Bought Shares Worth $1,249,934, According to a Recent SEC Filing	28/09/23
Acasti Announces $7.5 Million Private Placement Equity Financing	26/09/23
Acasti Pharma Inc. announced that it has received $7.499388 million in funding from SS Pharma LLC, Shore Pharma LLC	25/09/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Acasti Pharma Inc Toronto S.E.

Actions

APO

CA00430K4028

Autres langues

Filtres